메뉴 건너뛰기
Journal of the Canadian Urological Association
Volumn 10, Issue 1-2February, 2016, Pages 60-65
A primer on tumour immunology and prostate cancer immunotherapy
Author keywords

[No Author keywords available]
Indexed keywords

EID: 84958541091     PISSN: 19116470     EISSN: None     Source Type: Journal    
DOI: 10.5489/cuaj.3418     Document Type: Review
Times cited : (10)
References (56)
  • 1
    • 84933505752 scopus 로고    scopus 로고
    • Current and emerging immunotherapies for castration-resistant prostate cancer
    • Saad F, Miller K. Current and emerging immunotherapies for castration-resistant prostate cancer. Urology 2015;85:976-86. http://dx.doi.org/10.1016/j.urology.2014.12.029.
    • (2015) Urology , vol.85 , pp. 976-986
    • Saad, F.1    Miller, K.2
  • 2
    • 84909638924 scopus 로고    scopus 로고
    • Recommendations on screening for prostate cancer with the prostate-specific antigen test
    • Canadian Task Force on Preventive Health Care. Recommendations on screening for prostate cancer with the prostate-specific antigen test. CMAJ 2014;186:1225-34. http://dx.doi.org/10.1503/cmaj.140703.
    • (2014) CMAJ , vol.186 , pp. 1225-1234
  • 3
    • 84919905442 scopus 로고    scopus 로고
    • PSA screening: And now…a message from our experts
    • Kapoor A, Siemens DR. PSA screening: And now…a message from our experts. Can Urol Assoc J 2014;8:387-8. http://dx.doi.org/10.5489/cuaj.2604.
    • (2014) Can Urol Assoc J , vol.8 , pp. 387-388
    • Kapoor, A.1    Siemens, D.R.2
  • 4
    • 84872078210 scopus 로고    scopus 로고
    • Abiraterone in metastatic prostate cancer without previous chemotherapy
    • Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2012;368:138-48. http://dx.doi.org/10.1056/NEJMoa1209096.
    • (2012) N Engl J Med , vol.368 , pp. 138-148
    • Ryan, C.J.1    Smith, M.R.2    De Bono, J.S.3
  • 5
    • 84928041587 scopus 로고    scopus 로고
    • The 2015 CUA-CUOG guidelines for the management of castration-resistant prostate cancer (CRPC)
    • Saad F, Chi KN, Finelli A, et al. The 2015 CUA-CUOG guidelines for the management of castration-resistant prostate cancer (CRPC). Can Urol Assoc J 2015;990-6. http://dx.doi.org/10.5489/cuaj.2526.
    • (2015) Can Urol Assoc J , pp. 990-996
    • Saad, F.1    Chi, K.N.2    Finelli, A.3
  • 7
    • 84885949797 scopus 로고    scopus 로고
    • Targeted cancer immunotherapy
    • Zigler M, Shir A, Levitzki A. Targeted cancer immunotherapy. Curr Opin Pharmacol 2013;13:504-10. http://dx.doi.org/10.1016/j.coph.2013.04.003.
    • (2013) Curr Opin Pharmacol , vol.13 , pp. 504-510
    • Zigler, M.1    Shir, A.2    Levitzki, A.3
  • 8
    • 79953151458 scopus 로고    scopus 로고
    • Cancer immunoediting: Integrating immunity’s roles in cancer suppression and promotion
    • Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: Integrating immunity’s roles in cancer suppression and promotion. Science 2011;331:1565-70. http://dx.doi.org/10.1126/science.1203486.
    • (2011) Science , vol.331 , pp. 1565-1570
    • Schreiber, R.D.1    Old, L.J.2    Smyth, M.J.3
  • 9
    • 84928770388 scopus 로고    scopus 로고
    • Neoantigens in cancer immunotherapy
    • Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 2015;348:69-74. http://dx.doi.org/10.1126/science.aaa4971.
    • (2015) Science , vol.348 , pp. 69-74
    • Schumacher, T.N.1    Schreiber, R.D.2
  • 10
    • 34248193253 scopus 로고    scopus 로고
    • Immune surveillance of tumours
    • Swann JB, Smyth MJ. Immune surveillance of tumours. J Clin Invest 2007;117:1137-46. http://dx.doi.org/10.1172/JCI31405.
    • (2007) J Clin Invest , vol.117 , pp. 1137-1146
    • Swann, J.B.1    Smyth, M.J.2
  • 11
    • 84922181550 scopus 로고    scopus 로고
    • Balancing the innate immune system in tumour development
    • Hagerling C, Casbon AJ, Werb Z. Balancing the innate immune system in tumour development. Trends Cell Biol 2014;25:214-20. http://dx.doi.org/10.1016/j.tcb.2014.11.001.
    • (2014) Trends Cell Biol , vol.25 , pp. 214-220
    • Hagerling, C.1    Casbon, A.J.2    Werb, Z.3
  • 12
    • 84926506596 scopus 로고    scopus 로고
    • Immune-mediated mechanisms influencing the efficacy of anticancer therapies
    • Coffelt SB, Visser KE. Immune-mediated mechanisms influencing the efficacy of anticancer therapies. Trends Immunol 2015;36:198-216. http://dx.doi.org/10.1016/j.it.2015.02.006.
    • (2015) Trends Immunol , vol.36 , pp. 198-216
    • Coffelt, S.B.1    Visser, K.E.2
  • 13
    • 84904406680 scopus 로고    scopus 로고
    • Tumour-associated macrophages: From mechanisms to therapy
    • Noy R, Pollard JW. Tumour-associated macrophages: From mechanisms to therapy. Immunity 2015;41:49-61. http://dx.doi.org/10.1016/j.immuni.2014.06.010.
    • (2015) Immunity , vol.41 , pp. 49-61
    • Noy, R.1    Pollard, J.W.2
  • 14
    • 84919457872 scopus 로고    scopus 로고
    • Molecular mechanisms that influence the macrophage m1-m2 polarization balance
    • Wang N, Liang H, Zen K. Molecular mechanisms that influence the macrophage m1-m2 polarization balance. Front Immunol 2014;5:614. http://dx.doi.org/10.3389/fimmu.2014.00614.
    • (2014) Front Immunol , vol.5 , pp. 614
    • Wang, N.1    Liang, H.2    Zen, K.3
  • 15
    • 84902546715 scopus 로고    scopus 로고
    • Targeting tumour-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy
    • Ries CH, Cannarile MA, Hoves S, et al. Targeting tumour-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 2014;25:846-59. http://dx.doi.org/10.1016/j.ccr.2014.05.016.
    • (2014) Cancer Cell , vol.25 , pp. 846-859
    • Ries, C.H.1    Cannarile, M.A.2    Hoves, S.3
  • 16
    • 84898995774 scopus 로고    scopus 로고
    • NK cell recognition of unconventional ligands
    • Huntington ND. NK cell recognition of unconventional ligands. Immunol Cell Biol 2014;92:208-9. http://dx.doi.org/10.1038/icb.2014.6.
    • (2014) Immunol Cell Biol , vol.92 , pp. 208-209
    • Huntington, N.D.1
  • 17
    • 84905500282 scopus 로고    scopus 로고
    • Does the immune system naturally protect against cancer?
    • Corthay A. Does the immune system naturally protect against cancer? Front Immunol 2014;5:1-8. http://dx.doi.org/10.3389/fimmu.2014.00197.
    • (2014) Front Immunol , vol.5 , pp. 1-8
    • Corthay, A.1
  • 18
    • 52649167708 scopus 로고    scopus 로고
    • CD4 T cells: Fates, functions, and faults
    • Zhu J, Paul WE. CD4 T cells: Fates, functions, and faults. Blood 2015;112:1557-70.
    • (2015) Blood , vol.112 , pp. 1557-1570
    • Zhu, J.1    Paul, W.E.2
  • 19
    • 74049164847 scopus 로고    scopus 로고
    • Regulatory T cells exert checks and balances on self-tolerance and autoimmunity
    • Wing K, Sakaguchi S. Regulatory T cells exert checks and balances on self-tolerance and autoimmunity. Nat Immunol 2010;11:7-13. http://dx.doi.org/10.1038/ni.1818.
    • (2010) Nat Immunol , vol.11 , pp. 7-13
    • Wing, K.1    Sakaguchi, S.2
  • 20
    • 77954721060 scopus 로고    scopus 로고
    • Regulatory T cells in tumour immunity
    • Nishikawa H, Sakaguchi S. Regulatory T cells in tumour immunity. Int J Cancer 2010;127:759-67. http://dx.doi.org/10.1002/ijc.25429.
    • (2010) Int J Cancer , vol.127 , pp. 759-767
    • Nishikawa, H.1    Sakaguchi, S.2
  • 21
    • 42949105127 scopus 로고    scopus 로고
    • Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
    • Hodi FS, Butler M, Oble DA, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. PNAS 2008;105:3005-10. http://dx.doi.org/10.1073/pnas.0712237105.
    • (2008) PNAS , vol.105 , pp. 3005-3010
    • Hodi, F.S.1    Butler, M.2    Oble, D.A.3
  • 22
    • 84892448554 scopus 로고    scopus 로고
    • Regulatory T cells in cancer immunotherapy
    • Nishikawa H, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Curr Opin Immunol 2014;27:1-7. http://dx.doi.org/10.1016/j.coi.2013.12.005.
    • (2014) Curr Opin Immunol , vol.27 , pp. 1-7
    • Nishikawa, H.1    Sakaguchi, S.2
  • 23
    • 56849090964 scopus 로고    scopus 로고
    • The role of NKT cells in tumour immunity
    • Terabe M, Berzofsky JA. The role of NKT cells in tumour immunity. Adv Cancer Res 2008;101:277-348. http://dx.doi.org/10.1016/S0065-230X(08)00408-9.
    • (2008) Adv Cancer Res , vol.101 , pp. 277-348
    • Terabe, M.1    Berzofsky, J.A.2
  • 24
    • 84921974687 scopus 로고    scopus 로고
    • Duality of the immune response in cancer: Lessons learned from skin
    • Medler TR, Coussens LM. Duality of the immune response in cancer: Lessons learned from skin. J Invest Dermatol 2014;134:E23-8. http://dx.doi.org/10.1038/skinbio.2014.5.
    • (2014) J Invest Dermatol , vol.134 , pp. E23-E28
    • Medler, T.R.1    Coussens, L.M.2
  • 25
    • 84935066963 scopus 로고    scopus 로고
    • Immune infiltration and prostate cancer
    • Strasner A, Karin M. Immune infiltration and prostate cancer. Front Oncol 2015;5:128. http://dx.doi.org/10.3389/fonc.2015.00128.
    • (2015) Front Oncol , vol.5 , pp. 128
    • Strasner, A.1    Karin, M.2
  • 26
    • 84893203731 scopus 로고    scopus 로고
    • Tumour-infiltrating B-cells are increased in prostate cancer tissue
    • Woo JR, Liss MA, Muldong MT, et al. Tumour-infiltrating B-cells are increased in prostate cancer tissue. J Transl Med 2014;12:30. http://dx.doi.org/10.1186/1479-5876-12-30.
    • (2014) J Transl Med , vol.12 , pp. 30
    • Woo, J.R.1    Liss, M.A.2    Muldong, M.T.3
  • 27
    • 84892416943 scopus 로고    scopus 로고
    • Rituximab for treating CD20+ prostate cancer with generalized lymphadenopathy: A case report and review of the literature
    • Dalgleish A, Featherstone P, Vlassov V, et al. Rituximab for treating CD20+ prostate cancer with generalized lymphadenopathy: A case report and review of the literature. Invest New Drugs 2014;32:1048-52. http://dx.doi.org/10.1007/s10637-014-0063-z.
    • (2014) Invest New Drugs , vol.32 , pp. 1048-1052
    • Dalgleish, A.1    Featherstone, P.2    Vlassov, V.3
  • 28
    • 0036852241 scopus 로고    scopus 로고
    • Cancer immunoediting: From immunosurveillance to tumour escape
    • Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: From immunosurveillance to tumour escape. Nat Immunol 2002;3:991-8. http://dx.doi.org/10.1038/ni1102-991.
    • (2002) Nat Immunol , vol.3 , pp. 991-998
    • Dunn, G.P.1    Bruce, A.T.2    Ikeda, H.3
  • 29
    • 34047220868 scopus 로고    scopus 로고
    • Cancer immuno-editing from immune surveillance to immune escape
    • Kim R, Emi M, Tanabe K. Cancer immuno-editing from immune surveillance to immune escape. Immunology 2007;121:1-14. http://dx.doi.org/10.1111/j.1365-2567.2007.02587.x.
    • (2007) Immunology , vol.121 , pp. 1-14
    • Kim, R.1    Emi, M.2    Tanabe, K.3
  • 30
    • 84938773709 scopus 로고    scopus 로고
    • Evolutionary determinants of cancer
    • Greaves M. Evolutionary determinants of cancer. Cancer Discov 2015;5:806-20. http://dx.doi.org/10.1158/2159-8290.CD-15-0439.
    • (2015) Cancer Discov , vol.5 , pp. 806-820
    • Greaves, M.1
  • 31
    • 0036911269 scopus 로고    scopus 로고
    • Increasing tumour antigen expression overcomes “ignorance” to solid tumours via cross-presentation by bone marrow-derived stromal cells
    • Spiotto MT, Yu P, Rowley DA, et al. Increasing tumour antigen expression overcomes “ignorance” to solid tumours via cross-presentation by bone marrow-derived stromal cells. Immunity 2002;17:737-47. http://dx.doi.org/10.1016/S1074-7613(02)00480-6.
    • (2002) Immunity , vol.17 , pp. 737-747
    • Spiotto, M.T.1    Yu, P.2    Rowley, D.A.3
  • 32
    • 0036378101 scopus 로고    scopus 로고
    • Immature, but not inactive: The tolerogenic function of immature dendritic cells
    • Mahnke K, Schmitt E, Bonifaz L, et al. Immature, but not inactive: The tolerogenic function of immature dendritic cells. Immunol Cell Biol 2002;80:477-83. http://dx.doi.org/10.1046/j.1440-1711.2002.01115.x.
    • (2002) Immunol Cell Biol , vol.80 , pp. 477-483
    • Mahnke, K.1    Schmitt, E.2    Bonifaz, L.3
  • 33
    • 84920956735 scopus 로고    scopus 로고
    • Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
    • Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014;515:563-7. http://dx.doi.org/10.1038/nature14011.
    • (2014) Nature , vol.515 , pp. 563-567
    • Herbst, R.S.1    Soria, J.C.2    Kowanetz, M.3
  • 34
    • 84937516588 scopus 로고    scopus 로고
    • A systematic review of immunotherapy in urologic cancer: Evolving roles for targeting of CTLA-4, PD-1/PD-L1, and HLA-G
    • Carosella ED, Ploussard G, LeMaoult J, et al. A systematic review of immunotherapy in urologic cancer: Evolving roles for targeting of CTLA-4, PD-1/PD-L1, and HLA-G. Eur Urol 2015;68:267-79. http://dx.doi.org/10.1016/j.eururo.2015.02.032.
    • (2015) Eur Urol , vol.68 , pp. 267-279
    • Carosella, E.D.1    Ploussard, G.2    Lemaoult, J.3
  • 35
    • 84927130807 scopus 로고    scopus 로고
    • Immune checkpoint targeting in cancer therapy: Toward combination strategies with curative potential
    • Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: Toward combination strategies with curative potential. Cell 2015;161:205-14. http://dx.doi.org/10.1016/j.cell.2015.03.030.
    • (2015) Cell , vol.161 , pp. 205-214
    • Sharma, P.1    Allison, J.P.2
  • 36
    • 76349109469 scopus 로고    scopus 로고
    • Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer
    • Tagawa ST, Beltran H, Vallabhajosula S, et al. Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer 2010;116:1075-83. http://dx.doi.org/10.1002/cncr.24795.
    • (2010) Cancer , vol.116 , pp. 1075-1083
    • Tagawa, S.T.1    Beltran, H.2    Vallabhajosula, S.3
  • 37
    • 33947529429 scopus 로고    scopus 로고
    • Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumours
    • Milowsky MI, Nanus DM, Kostakoglu L, et al. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumours. J Clin Oncol 2007;25:540-7. http://dx.doi.org/10.1200/JCO.2006.07.8097.
    • (2007) J Clin Oncol , vol.25 , pp. 540-547
    • Milowsky, M.I.1    Nanus, D.M.2    Kostakoglu, L.3
  • 38
    • 77954939175 scopus 로고    scopus 로고
    • Prostate cancer as a model for tumour immunotherapy
    • Drake CG. Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol 2010;10:580-93. http://dx.doi.org/10.1038/nri2817.
    • (2010) Nat Rev Immunol , vol.10 , pp. 580-593
    • Drake, C.G.1
  • 39
    • 34249868241 scopus 로고    scopus 로고
    • Adoptive T cell therapy for cancer in the clinic
    • June CHC. Adoptive T cell therapy for cancer in the clinic. J Clin Invest 2007;117:1466-76. http://dx.doi.org/10.1172/JCI32446.
    • (2007) J Clin Invest , vol.117 , pp. 1466-1476
    • June, C.H.C.1
  • 40
    • 84876325876 scopus 로고    scopus 로고
    • Chimeric antigen receptor-modified T cells for acute lymphoid leukemia
    • Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368:1509-18. http://dx.doi.org/10.1056/NEJMoa1215134.
    • (2013) N Engl J Med , vol.368 , pp. 1509-1518
    • Grupp, S.A.1    Kalos, M.2    Barrett, D.3
  • 41
    • 85051750761 scopus 로고    scopus 로고
    • Sipuleucel-T immunotherapy for castration-resistant prostate cancer
    • Kantoff P, Higano CS, Shore N, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010:2373-83. http://dx.doi.org/10.1056/NEJMoa1407764.
    • (2010) N Engl J Med , pp. 2373-2383
    • Kantoff, P.1    Higano, C.S.2    Shore, N.3
  • 42
    • 84893091990 scopus 로고    scopus 로고
    • Economic evaluation of sipuleucel-T immunotherapy in castration-resistant prostate cancer
    • Holko P, Kawalec P. Economic evaluation of sipuleucel-T immunotherapy in castration-resistant prostate cancer. Expert Rev Anticancer Ther 2014;14:63-73. http://dx.doi.org/10.1586/14737140.2014.856270.
    • (2014) Expert Rev Anticancer Ther , vol.14 , pp. 63-73
    • Holko, P.1    Kawalec, P.2
  • 43
    • 84857397717 scopus 로고    scopus 로고
    • Interdisciplinary critique of sipuleucel-T as immunotherapy in castrationresistant prostate cancer
    • Huber ML, Haynes L, Parker C, et al. Interdisciplinary critique of sipuleucel-T as immunotherapy in castrationresistant prostate cancer. J Natl Cancer Inst 2012;104:273-9. http://dx.doi.org/10.1093/jnci/djr514.
    • (2012) J Natl Cancer Inst , vol.104 , pp. 273-279
    • Huber, M.L.1    Haynes, L.2    Parker, C.3
  • 44
    • 34447123763 scopus 로고    scopus 로고
    • Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer
    • Small EJ, Sacks N, Nemunaitis J, et al. Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res 2007;13:3883-91. http://dx.doi.org/10.1158/1078-0432.CCR-06-2937.
    • (2007) Clin Cancer Res , vol.13 , pp. 3883-3891
    • Small, E.J.1    Sacks, N.2    Nemunaitis, J.3
  • 45
    • 52049090425 scopus 로고    scopus 로고
    • Phase I/II dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer
    • Higano CS, Corman JM, Smith DC, et al. Phase I/II dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 2008;113:975-84. http://dx.doi.org/10.1002/cncr.23669.
    • (2008) Cancer , vol.113 , pp. 975-984
    • Higano, C.S.1    Corman, J.M.2    Smith, D.C.3
  • 46
    • 68549135290 scopus 로고    scopus 로고
    • Integrated data from 2 randomized, double-blind, placebocontrolled, phase III trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer
    • Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebocontrolled, phase III trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009;115:3670-9. http://dx.doi.org/10.1002/cncr.24429.
    • (2009) Cancer , vol.115 , pp. 3670-3679
    • Higano, C.S.1    Schellhammer, P.F.2    Small, E.J.3
  • 47
    • 84921903497 scopus 로고    scopus 로고
    • DNA vaccine for cancer immunotherapy
    • Yang B, Jeang J, Yang A, et al. DNA vaccine for cancer immunotherapy. Hum Vaccin Immunother 2014;10:3153-64. http://dx.doi.org/10.4161/21645515.2014.980686.
    • (2014) Hum Vaccin Immunother , vol.10 , pp. 3153-3164
    • Yang, B.1    Jeang, J.2    Yang, A.3
  • 48
    • 84904387492 scopus 로고    scopus 로고
    • Preclinical and clinical development of DNA vaccines for prostate cancer
    • [Epub ahead of print]
    • Colluru VT, Johnson L, Olson B, et al. Preclinical and clinical development of DNA vaccines for prostate cancer. Urol Oncol 2015. [Epub ahead of print].
    • (2015) Urol Oncol
    • Colluru, V.T.1    Johnson, L.2    Olson, B.3
  • 49
    • 34548452131 scopus 로고    scopus 로고
    • Clinical safety of a viral vector based prostate cancer vaccine strategy
    • Arlen PM, Skarupa L, Pazdur M, et al. Clinical safety of a viral vector based prostate cancer vaccine strategy. J Urol 2007;178:1515-20. http://dx.doi.org/10.1016/j.juro.2007.05.117.
    • (2007) J Urol , vol.178 , pp. 1515-1520
    • Arlen, P.M.1    Skarupa, L.2    Pazdur, M.3
  • 50
    • 77949895922 scopus 로고    scopus 로고
    • Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer
    • Kantoff P, Schuetz T, Blumenstein B, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010;28:1099-105. http://dx.doi.org/10.1200/JCO.2009.25.0597.
    • (2010) J Clin Oncol , vol.28 , pp. 1099-1105
    • Kantoff, P.1    Schuetz, T.2    Blumenstein, B.3
  • 51
    • 21044460010 scopus 로고    scopus 로고
    • The B7 family of immune-regulatory ligands
    • Collins M, Ling V, Carreno BM. The B7 family of immune-regulatory ligands. Genome Biol 2005;6:223. http://dx.doi.org/10.1186/gb-2005-6-6-223.
    • (2005) Genome Biol , vol.6 , pp. 223
    • Collins, M.1    Ling, V.2    Carreno, B.M.3
  • 52
    • 55949083407 scopus 로고    scopus 로고
    • Anti-cytotoxic T-lymphocyte antigen-4 antibody: The first in an emerging class of immunomodulatory antibodies for cancer treatment
    • Fong L, Small EJ. Anti-cytotoxic T-lymphocyte antigen-4 antibody: The first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol 2008;26:5275-83. http://dx.doi.org/10.1200/JCO.2008.17.8954.
    • (2008) J Clin Oncol , vol.26 , pp. 5275-5283
    • Fong, L.1    Small, E.J.2
  • 53
    • 84928774156 scopus 로고    scopus 로고
    • The future of immune checkpoint therapy
    • Sharma P, Allison JP. The future of immune checkpoint therapy. Science 2015;348:56-61. http://dx.doi.org/10.1126/science.aaa8172.
    • (2015) Science , vol.348 , pp. 56-61
    • Sharma, P.1    Allison, J.P.2
  • 54
    • 84858007569 scopus 로고    scopus 로고
    • Interferon-gamma-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway
    • Chen J, Feng Y, Lu L, et al. Interferon-gamma-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway. Immunobiology 2012;217:385-93. http://dx.doi.org/10.1016/j.imbio.2011.10.016.
    • (2012) Immunobiology , vol.217 , pp. 385-393
    • Chen, J.1    Feng, Y.2    Lu, L.3
  • 55
    • 84936147067 scopus 로고    scopus 로고
    • Combined nivolumab and ipilimumab or monotherapy in untreated melanoma
    • Larkin J, Chiarion-Sileni V, Gonzalex R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;73:23-3 http://dx.doi.org/10.1056/NEJMoa1504030.
    • (2015) N Engl J Med , vol.73
    • Larkin, J.1    Chiarion-Sileni, V.2    Gonzalex, R.3
  • 56
    • 84958552957 scopus 로고
    • Dr. Coley’s toxins
    • Goodfield J. Dr. Coley’s toxins. Science 1984:226-68.
    • (1984) Science , pp. 226-268
    • Goodfield, J.1

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.